Atherosclerosis regression: Is low-density lipoprotein or high-density lipoprotein the answer?

Stephen J. Nicholls, E. Murat Tuzcu, Steven E. Nissen

Research output: Contribution to journalReview ArticleResearchpeer-review

11 Citations (Scopus)


Lowering low-density lipoprotein cholesterol is the cornerstone of risk modification in patients with established coronary artery disease. Considerable attention is currently focused on developing pharmacologic agents that promote the biologic activity of high-density lipoprotein. Advances in imaging of the artery wall provide the opportunity to evaluate the impact of medical therapies on serial changes in plaque burden. A number of reports describe the favorable effects of interventions that lower low-density lipoprotein cholesterol or promote the biologic activity of high-density lipoprotein. The current state of evidence defining the relative contribution of changes in plasma lipids on the tendency to plaque regression is review.

Original languageEnglish
Pages (from-to)266-273
Number of pages8
JournalCurrent Atherosclerosis Reports
Issue number4
Publication statusPublished - 1 Oct 2007
Externally publishedYes

Cite this